Ticagrelor NDC 43598-480

NDC codes

FDA NDC Directory

Product NDC (as listed)43598-480Labeler and product segments. Claims need a package NDC.

Product NDC at billing width43598-0480Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
43598-480-18	43598048018	180 TABLET in 1 BOTTLE (43598-480-18)Marketed from Apr 30, 2025
43598-480-60	43598048060	60 TABLET in 1 BOTTLE (43598-480-60)Marketed from Apr 30, 2025
43598-480-78	43598048078	10 BLISTER PACK in 1 CARTON (43598-480-78) / 10 TABLET in 1 BLISTER PACKMarketed from Apr 30, 2025
43598-480-79	43598048079	1 BLISTER PACK in 1 CARTON (43598-480-79) / 10 TABLET in 1 BLISTER PACKMarketed from Apr 30, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ticagrelor
Generic name (nonproprietary): ticagrelor
Active ingredients: Ticagrelor — 90 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Dr. Reddys Laboratories Inc
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 208541
Marketing start: Apr 30, 2025
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 3A4 Inhibitors (Mechanism)Decreased Platelet Aggregation (Physiologic effect)P-Glycoprotein Inhibitors (Mechanism)P2Y12 Receptor Antagonists (Mechanism)
Identifiers: Product ID 43598-480_505b2d2b-bc2d-41dd-9384-a90d3d4d91ecSPL ID 505b2d2b-bc2d-41dd-9384-a90d3d4d91ecSPL set ID 1225fd45-9b56-1671-ee77-cd0c9f2174a5RxCUI 1116635, 1666332UNII GLH0314RVCUPC 0343598480602, 0343598629605
Pharmacologic class: P2Y12 Platelet Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N443598048018 followed by a unit qualifier and the quantity

Package 43598-0480-18. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 30, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Ticagrelor is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (MI). For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. ( 1.1 ) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor was established in a population with type 2 diabetes mellitus (T2DM). ( 1.2 …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 208541

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 208541
Product	Strength	Form · route	Labeler	Product NDC
Ticagrelor	Ticagrelor 60 mg/1	TabletOral	Dr. Reddys Laboratories Inc	43598-629